EMA IDMP Roadmap 2026: Preparing for PMS and FHIR Submissions
EMAのIDMP移行ロードマップ：PMSとFHIR準拠への準備
The EMA published the IDMP Roadmap 2026, detailing requirements for Post-Market Surveillance (PMS) and FHIR data submissions.
Summary
The European Medicines Agency (EMA) is accelerating the transition away from legacy systems in product lifecycle management. By 2026, product data management must shift toward a structured 'Digital Twin' model based on FHIR standards.
Key Players
Details
According to the EMA’s latest roadmap, medicinal portfolio management is undergoing a fundamental pivot from scattered, narrative records to unified, structured 'Digital Twin' data objects. This transition mandates the decommissioning of legacy systems like SIAMED and xEVMPD. A critical aspect is the structuring of Product Information (IDMP) data; static records are being replaced by high-fidelity, structured data objects based on HL7 FHIR standards. Successful migration requires not just technical adaptation but also qualitative data improvement based on FAIR principles (Findable, Accessible, Interoperable, Reusable). FHIR provides the 'format' for data exchange, while FAIR defines the standard for the data itself. Key requirements include assigning Globally Unique and Persistent Identifiers (PID) to all elements (Findable), enabling automated API-based write endpoints (Accessible), and ensuring interoperability through common vocabularies and models (Interoperable). This transformation culminates in a 'hard gate' by June 2026, when the submission of FHIR structured data via the PMS API becomes mandatory. Companies must remediate legacy data according to FAIR principles, undergo technical validation, and establish automated API-based submission systems.
Technology Note
FHIR（Fast Healthcare Interoperability Resources）は医療データ交換の国際標準。このエントリの関連技術: FHIR
Original content copyright by respective publishers